文献速递造血干细胞移植与细胞治疗血栓与止血

体内转导造血干细胞来源的红系细胞高水平生产蛋白

High-level protein production in erythroid cells derived from in vivo transduced hematopoietic stem cells.
PubMed 文献 · Blood Adv · 2019-01-01

研究开发了一种体内造血干细胞(HSC)转导方法,通过动员HSC至外周血并静脉注射整合型辅助依赖腺病毒(HDAd5/35++)载体,利用β-珠蛋白调控元件将转基因表达导向红系细胞。在hCD46转基因小鼠中实现了红系特异性GFP持续表达及红细胞内积累,并获得稳定的超生理血浆浓度的人凝血因子VIII(ET3),且不影响红细胞生成;在血友病A小鼠中观察到出血表型纠正,尽管存在高滴度抗ET3抗体。

要点

  • 体内HSC转导结合红系特异性表达可实现治疗蛋白高水平全身释放。
  • 红系细胞生产ET3未影响红细胞生成,且可纠正血友病A小鼠出血表型。
  • 该方法有望拓展至其他需血液中高浓度治疗蛋白的遗传或获得性疾病。

核心结论

  • 利用β-珠蛋白调控元件将转基因表达导向HSC来源的红系细胞,可在体内实现治疗蛋白的高水平生产。
  • 在血友病A小鼠中,红系细胞生产的ET3可纠正出血表型,尽管存在高滴度抗ET3抗体。

研究设计与样本

  • 研究采用体内HSC转导方法:动员HSC至外周血后静脉注射整合型辅助依赖腺病毒HDAd5/35++载体,通过SB100x转座酶实现转基因整合,并可通过体内选择提高标记率。
  • 在hCD46转基因小鼠中评估红系特异性GFP表达,在hCD46+/+/F8-/-血友病A小鼠中评估ET3表达及出血纠正。

主要发现

  • 在hCD46转基因小鼠中实现红系谱系特异性GFP持续表达及红细胞内GFP蛋白积累。
  • 体内HSC转导/选择后,hCD46转基因小鼠血浆中生物工程人凝血因子VIII(ET3)达到稳定的超生理浓度。
  • 红系细胞高水平生产ET3不影响红细胞生成。
  • 在hCD46+/+/F8-/-血友病A小鼠中,尽管血浆抗ET3抗体滴度高,仍观察到出血表型纠正。

临床怎么用

  • 该策略可能为血友病A基因治疗提供新思路,并适用于其他需血液中高浓度治疗蛋白的疾病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We developed an in vivo hematopoietic stem cell (HSC) transduction approach that involves HSC mobilization from the bone marrow into the peripheral bloodstream and the IV injection of an integrating, helper-dependent adenovirus (HDAd5/35++) vector system. HDAd5/35++ vectors target human CD46, a receptor that is abundantly expressed on primitive HSCs. Transgene integration is achieved by a hyperactive Sleeping Beauty transposase (SB100x) and transgene marking in peripheral blood cells can be increased by in vivo selection. Here we directed transgene expression to HSC-derived erythroid cells using β-globin regulatory elements. We hypothesized that the abundance and systemic distribution of erythroid cells can be harnessed for high-level production of therapeutic proteins. We first demonstrated that our approach allowed for sustained, erythroid-lineage specific GFP expression and accumulation of GFP protein in erythrocytes. Furthermore, after in vivo HSC transduction/selection in hCD46-transgenic mice, we demonstrated stable supraphysiological plasma concentrations of a bioengineered human factor VIII, termed ET3. High-level ET3 production in erythroid cells did not affect erythropoiesis. A phenotypic correction of bleeding was observed after in vivo HSC transduction of hCD46+/+/F8-/- hemophilia A mice despite high plasma anti-ET3 antibody titers. This suggests that ET3 levels were high enough to provide sufficient noninhibited ET3 systemically and/or locally (in blood clots) to control bleeding. In addition to its relevance for hemophilia A gene therapy, our approach has implications for the therapy of other inherited or acquired diseases that require high levels of therapeutic proteins in the blood circulation.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Wang H, Liu Z, Li C, et al. High-level protein production in erythroid cells derived from in vivo transduced hematopoietic stem cells. Blood Adv. 2019. PMID: 31585952. doi:10.1182/bloodadvances.2019000706

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。